Evidence map›Paper›PMID 41126279›Full record

ReviewStem cell research & therapy2025

MiRNA delivery systems in cancer stem cell therapy: exosomes versus chitosan nanoparticles.

Maryam Valizadeh-Otaghsara, Mostafa Haji Molla Hoseini, Saeed Karima, Hakimeh Zali, Kamyar Khoshnevisan, Samira Mohammadi-Yeganeh

Abstract readReview
In one paragraph

Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maryam Valizadeh-OtaghsaraDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mostafa Haji Molla HoseiniMedical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Saeed KarimaDepartment of Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hakimeh ZaliDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kamyar KhoshnevisanMedical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Samira Mohammadi-YeganehCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. s.mohammadiyeganeh@sbmu.ac.ir.

Funding

Iran National Science Foundation 4028901Shahid Beheshti University of Medical Sciences 43008093
6 · The paper itself

Abstract

Cancer stem cells (CSCs), refer to small subpopulations of cancer cells within a tumor mass representing stemness properties such as high self-renewal capacities, differentiation potential, metastasis, therapy resistance, and tumor recurrence. These cells are the main reason for cancer treatment failure and the inefficacy of traditional therapeutic approaches. Accordingly, focusing on molecular mechanisms underlying CSCs and targeting them is the new era in the field of cancer. MicroRNAs (miRNAs) are a class of noncoding RNAs that play an important role in the formation and progression of CSCs by regulating the expression of stemness markers and critical genes implicated in CSC signaling pathways. Many studies have reported that some miRNAs have aberrant expression in CSCs. Dysregulated miRNAs can be a promising candidate as a therapeutic target for eradicating CSCs, but their delivery into CSCs could be challenging. Notably, numerous studies have shown that natural nanoparticles such as exosomes and chitosan nanoparticles (CSNPs) are among the most extensively exploited nano vehicles for miRNA delivery. In the present review, we focus specifically on CSNPs- and exosome-based CSC-targeted therapies and provide the key advantages and shortcomings of these systems as miRNA delivery systems for targeting CSCs.

Indexed as

ChitosanExosomesMicroRNAsNanoparticlesNeoplasmsNeoplastic Stem CellsAnimalsHumansChitosanMicroRNAsCancer stem cellChitosanExosomeMiRNANanotechnology

Identifiers

PMID41126279
PMCPMC12542416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.